PCN144 - COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREA
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.227
https://www.valueinhealthjournal.com/article/S1098-3015(18)33527-7/fulltext
Section Title :
Section Order :
1671
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33527-7&doi=10.1016/j.jval.2018.09.227